Purified cardiac sarcolemmal membrane vesicles were used to determine if specific prostaglandin (PG) receptors are present on the myocyte. Two binding sites for PGEj were identified in isolated bovine sarcolemmal membranes: a high-affinity site with a dissociation constant (AJ of 032 nM and a maximum binding (B^J of 376 fmol/mg of protein and a lower-affinity site with a K A of 3.41 nM and a B^ of 2,112 fmol/mg of protein. In competition experiments, unlabeled PGE, displaced [ . We conclude that the isolated cardiac sarcolemmal membrane contains a high-affinity binding site for PGEj that is functionally coupled to adenylate cyclase. The binding site is stereospecific and probably recognizes the 9-keto,ll-hydroxyl portion of the ring structure of these prostaglandins. (Circulation Research 1989-,65:538-545) 
H]PGEj binding. Phosphorylation of the membrane with protein kinase A also decreased specific ['HJPGEj binding. At concentrations of PGE} that occupy the high-affinity site, sarcolemmal adenylate cyclase activity was inhibited in the presence of 5'-guanylylimidodiphosphate [Gpp(NH)p]. We conclude that the isolated cardiac sarcolemmal membrane contains a high-affinity binding site for PGEj that is functionally coupled to adenylate cyclase. The binding site is stereospecific and probably recognizes the 9-keto,ll-hydroxyl portion of the ring structure of these prostaglandins.
(Circulation Research 1989-,65:538-545) E icosanoids appear to play an important role in the heart physiologically and during pathological conditions such as ischemia. 1 -4 The prostaglandins (PGs) act directly on the myocardium as well as the coronary vasculature, 1 while thromboxane (TX) A 2 is a potent coronary vasoconstrictor. 5 During ischemia, eicosanoid production increases, '• 5 -6 possibly due to an increase in the release of arachidonic acid from myocardial phospholipids. 7 In isolated coronary arteries, arachidonic acid has been shown to predominantly synthesize PGI 2 , PGE2, and TXA 2 . 6 Despite the extensive work performed on myocardial eicosanoid release and synthesis, relatively little is known about their mechanism and site of action. In several tissues, the eicosanoids have been shown to exert their action via specific plasma membrane receptors. 8 - 11 To our knowledge, no studies have determined the existence of eicosanoid receptors in the heart or the mechanism by which potential receptors are coupled to subceUular events. Unlike TXA 2 and PGIj, which are extremely labile compounds, PGE2 is relatively stable. For this reason, we wanted to determine the presence of PGEj receptors in the myocardial membrane and the mechanism by which PGE2 exerts its action on the heart. The action of PGE2 on various myocardial tissue preparations has been extensively investigated (for review, see Kafmazyn and Dhalla 1 ). Addition of PGE2 to in vitro perfused hearts has both a positive inotropic 1214 and a chronotropic 15 -17 effect. Direct coronary artery injection of PGE2 in vivo immediately increases the force of contraction, although heart rate may increase or decrease, depending on the experimental model used. 18 - 19 Several studies suggest a direct cellular action of prostaglandins on the heart, which includes alterations in glucose oxidation, myocardial O 2 consumption, myocardial The mechanism by which prostaglandins influence the myocardium is unknown. In this study, we report the presence of high-affinity PGE2 receptors in pure cardiac sarcolemmal membrane vesicles that are coupled to the catalytic subunit of adenylate cyclase on the cytosolic surface of the sarcolemma. 
Materials and Methods

Preparation of Cardiac Sarcolemmal Membrane Vesicles
Sarcolemmal vesicles were isolated from bovine hearts (left ventricle) by a sucrose flotation method. 23 The buffers used in the preparation contained 0.1 mM phenylmethylsulfonyl fluoride (PMSF). Vesicles were suspended at 3-5 mg protein/ml in 100 mM NaCl and 20 mM HEPES (pH 7.4), frozen in liquid nitrogen, and stored at -70° C. The sarcolemmal vesicles used were tightly sealed and, as shown in Table 1 , possess a Ca 2+ /calmodulin-dependent ATPase, an electrogenic Na + -Ca 2+ exchanger, and an ATP-dependent Ca 2+ uptake. 24 The sidedness of the sarcolemmal vesicles was estimated from ouabain inactivation of the Na + ,K + -dependent ATPase activity assayed in the presence of monensin, a Na + ionophore. 23 The In preparations used for measurement of the effects of PGE2 on adenylate cyclase, 10~6 M PGEj was included in all buffers used to isolate the sarcolemmal vesicles. This was done because studies of Negishi et al 26 suggest that binding of PGE2 to its receptor maintains coupling between the receptor and other membrane proteins involved in the signal transduction. To remove membrane-bound PGE2 after isolation, the vesicles (approximately 6 mg of protein) were washed in 50 ml of 100 mM NaCl and 20 mM HEPES (pH 7.4) and centrifuged at 200,00Qg for 35 minutes. This wash was repeated, and the vesicles were resuspended in the same medium, frozen in liquid nitrogen, and stored at -70° C. Subsequent PGEj binding studies demonstrated that these final wash procedures dissociated PGE2 from the receptor (data not shown). Control sarcolemmal vesicles were subjected to an identical procedure, except PGE2 was excluded from all the isolation buffers. Protein was measured by the method of Lowry et al. 27 Cultured aortic endothelial cells (a generous gift of C. Krueger and D. Cook, Department of Pharmacology, University of Alberta) were maintained in culture using Dulbecco's medium, 10% fetal calf serum, and 1% penicillin-streptomycin. at one half maximal speed with a Tekmar tissumizer (Cincinnati, Ohio). The suspension was subsequently centrifuged at l,000g. The resultant supernatant was centrifuged at 210,000^, and the crude microsomal pellet was resuspended in 250 mM sucrose and 20 mM MOPS (pH 7.4). Mitochondria were isolated from bovine ventricle by differential centrifugation. Ventricular muscle was homogenized in a sucrose-MOPS buffer, as described above, and centrifuged at l,Q0Qg. The resultant supernatant was subsequently centrifuged at 10,000^. The pelleted mitochondria were then resuspended in 250 mM sucrose and 20 mM MOPS (pH 7.4), as used for 
Measurement of Prostaglandin Binding
Receptor binding was assayed in 200 yA of medium containing 100 mM NaCl, 20 mM HEPES (pH 7.4), and varying concentrations of [ were added, and the mixture was incubated for 60 minutes at 37° C. The reaction was terminated by pipetting an aliquot of the mixture onto Millipore filters (0.3-fim pore size, Bedford, Massachusetts). Filters were washed with 10 ml of buffer containing 100 mM NaCl and 20 mM HEPES (pH 7.4), dried, and counted with standard liquid scintillation techniques. Specific binding was determined by subtracting binding in the presence of an excess of the appropriate prostaglandin (10~6 or 10" 5 M) from total binding. Preliminary studies were performed to determine optimal binding conditions. As shown in Figure 1A , binding of pHJPGEj to sarcolemmal membrane was complete by 50 minutes of incubation and was also linearly dependent on sarcolemmal protein content ( Figure IB) . Binding characteristics of [ 3 H]PGE2 to the membrane were identical between pH 7.0 and 8.5 ( Figure 1C ). Based on this data, all subsequent binding assays were carried out for 60 minutes at 37° C and pH 7.4 with 2.5 ng sarcolemmal protein. In the phosphorylation studies, prior to PGE2 binding, membranes were preincubated for 5 minutes at room temperature in buffer containing 3 mM MgCl 2 , 0.1 mM ethylene glycolbis-O-aminoethyl ether)-A^,A^,A^',A^'-tetraacetic acid (EGTA), 0.1 mM ATP, 10 fiM cAMP, and 100 ^g protein kinase A. Control experiments determined that MgCl 2 , EGTA, ATP, and AMP-PNP alone did not affect pHJPGEj binding (data not shown). In experiments involving protein digestion, prior to PGE2 binding, sarcolemmal vesicles were preincubated for 30 minutes at 37° C with either trypsin or papain (1 mg/mg sarcolemmal protein). Proteolytic digestion was stopped by addition of 0.1 mM PMSF, followed by centrifugation for 60 minutes at 200,000g.
Measurement of Cardiac Sarcolemmal Adenylate Cyclase Activity
Sarcolemmal vesicles were preincubated for 15 minutes in the presence of 1 mg or 0.3 mg alamethicin/mg protein, then added to an incubation medium containing 50 mM Tris-HQ (pH 7.4), 100 mM NaCl, 6 mM MgCl 2 , 8 mM KC1, 0.4 mg/ml bovine serum albumin, 0.4 mM dithiothreitol, 0.7 mM EGTA, 2.5 mM creatine, 0.095 mg creatine kinase, 1 mM isobutyl methylxanthine, and 1 mM [ 32 P]ATP (300,000 dpm) in a final volume of 150 /tl. Samples were incubated at 30° C for various time periods, and the reaction was terminated with 100 jil ice-cold 2% sodium dodecyl sulfate containing 45 mM ATP and 1.3 mM cAMP. The [^c A M P formed by the reaction was separated from [^PJATP and 32 P by sequential chromatography on Dowex-50w hydrogen cation exchange and neutral alumina columns. 28 
Separation of Prostaglandins by High-Performance Liquid Chromatography
Stability of the labeled prostaglandins under the binding conditions was determined by freezing an aliquot of the incubation medium in liquid nitrogen before filtering and subsequently separating the prostaglandin by high-performance liquid chromatography (HPLC). Experiments were performed on a Waters model 840 HPLC (Milford, Massachusetts) with a Novapak 10-/xm C-18 column (Milford, Massachusetts), with an on-line detector and Berthold HPLC radioactive monitor LB 505 (Nashua, New Hampshire).
[ 3 H]PGEj was separated from the incubation medium with octadecyltrichlorosilane Sep-Pak C-18 cartridges (Waters Instruments, Milford, Massachusetts) preequilibrated with 95% ethanol. Samples stored in liquid nitrogen were thawed, acidified with IN HC1, and passed through the cartridge. The cartridge was then washed with 6 ml 10% ethanol, 6 ml distilled H 2 O, and 6 ml hexane. Prostaglandins were eluted from the cartridge with 6 ml acetone. The acetone was then evaporated under nitrogen, and the residue dissolved in 500 /i.1 acetonitrile. Prostaglandins were separated with a 2-minute isocratic elution at a flow rate of 1.5 ml/min, a 5-minute gradient from 25-50% acetonitrile, and a 15-minute gradient from 50-100% acetonitrile. Under these conditions, PGE2 eluted at 9.64 minutes, PGFâ t 8.34 minutes, and PGD 2 at 8.97 minutes. Regardless of the radiolabeled prostaglandin used, 70-90% of the label coeluted with the corresponding unlabeled standard, thus ruling out significant degradation of the prostaglandins during the binding assay. 
Results
Prostaglandin E 2 Binding
The specificity of PGE2 binding was determined by incubation of sarcolemmal membranes with (Figure 2 ). Unlabeled PGEi displaced pHJPGEj at concentrations similar to those for unlabeled PGEj. PGF^ (which differs from PGE2 in that the 9-keto group is replaced by a 9-hydroxyl group) had a much lower affinity for the PGEj binding site. Similarly, PGD 2 also had a low affinity for the PGE; binding site. High concentrations of 6-keto-PGF, a (the stable PGI 2 metabolite) were necessary to displace [ To further characterize the binding of PGEj to sarcolemmal membrane, a saturation analysis was performed, from which a Scatchard plot was constructed ( Figure 3) . A curvilinear plot for PGFĉ ould be constructed that resolved into two distinct binding sites (Figure 3) . Analysis by linear regression revealed a high-affinity site (K^ of 0.32 nM, Bô f 376 fmol/mg protein) and a low-affinity site (K d of 3.41 nM, B^ of 2,112 fmol/mg protein).
To confirm that PGE? binding occurred at a membrane protein, sarcolemmal vesicles were digested with trypsin or papain (1 mg protease/mg protein). Trypsin pretreatment resulted in a threefold decrease in specific binding (from 423 to 144 
H]prostaglandin (PG) E 2 binding to cardiac sarcolemmal vesicles (SL). Binding of 1 3 H]PGE 2 was carried out as described in "Materials and Methods. " Specific binding was determined by subtracting binding in the presence of 10" 6 M PGE 2 from total binding. The experiment is representative of five experiments. Inset is a Scatchard plot derived from the saturation curve with B/F (bound/free). Scatchard curves were analyzed by multiple-regression linear analysis.
fmol/mg protein). Papain pretreatment also resulted in a twofold decrease in specific binding (from 423 to 194 fmol/mg protein). pHJPGE? binding was also determined in cardiac sarcolemmal membrane treated with various concentrations of detergents. Binding characteristics could be maintained in membrane soiubilized with 8 mM 3-[(3-cholamidopropyl)-dimethylammonio]-l-propanesulfonate, 8 mM Triton X-100, or 17 mM octylglucoside (M. Michalak, unpublished observations).
Studies by Tomlins et al 29 have demonstrated that cardiac sarcolemmal vesicle preparations obtained from intact heart contain some endothelial cell membrane contamination. The degree of endothelial membrane contamination was determined by measuring angiotensin-converting enzyme activity. Using this assay, we have measured endothelial membrane contamination in our preparation and found it to be less than 5% of the total membrane protein (J. Charuk, S. Howlett, and M. Michalak (Figure 4) , suggesting that PGE, binds to the same receptor.
Prostaglandin E 2 Effects on Adenylate Cyclase Activity
The effects of PGEi on cardiac sarcolemmal adenylate cyclase activity was determined. To perform these experiments, sarcolemmal membranes Results are mean+SEM of four experiments. Cardiac sarcolemmal vesicles were preincubated in the presence or absence of 0.3 mg alamcthidn/mg protein for 15 minutes before measurement of adenylate cyclase activity. Isoproterenol, when used, was added at a concentration of 10" 6 M.
were preincubated with the nonspecific ionophore alamethicin (0.3 mg/mg sarcolemmal protein). Alamethicin forms protein channels through the membrane and enables one to measure both prostaglandin binding localized on the extracellular surface of the membrane and adenylate cyclase activity localized on the intracellular surface of the membrane. As shown in Table 2 , alamethicin pretreatment resulted in an approximately twofold increase in isoproterenol-stimulated adenylate cyclase activity. Addition of Gpp(NH)p (a nonhydrolyzable analogue of GTP) to intact or alamethicinpermeabilized sarcolemma resulted in a 10-fold increase in isoproterenol-stimulated adenylate cyclase activity ( Table 2 ). The effects of PGE2 on cardiac sarcolemmal adenylate cyclase as initially determined showed great variability. Possibly, interaction of the PGE receptor with Gj (and G s ) proteins may become uncoupled during isolation of the cardiac sarcolemmal vesicles. Negishi et al 26 suggest that in adrenal medulla membranes, occupancy of the receptor with ligand can preserve receptor G-protein coupling. To test this possibility, sarcolemmal vesicles were prepared in the presence of 10~6 M PGEj, then washed in the absence of PGE^ before experimentation. PGE2 binding experiments revealed that PGE2 bound to the receptor prior to isolation was removed by the final washes (data not shown). Figure 5 shows the effects of PGE2 on adenylate cyclase activity in permeabilized sarcolemma] vesicles isolated in the presence of PGE^. PGE2 consistently inhibited adenylate cyclase activity at concentrations of PGE2 that occupy the high-affinity receptor.
Discussion
We have demonstrated that myocardial sarcolemmal vesicles contain high-affinity binding sites for PGEj. Because PGE2 predominates under physiological conditions, it is most likely this prostaglandin that binds to the sarcolemmal membrane in vivo. The source of PGE2 remains undefined, but may originate from the heart itself. Coronary vessels are a major source of locally produced PGE2 that may interact with receptors on the myocyte. 30 Scatchard analysis of PGE2 binding suggests that two distinct binding sites exist, one of high affinity and low capacity and the other of low affinity and high capacity. The two binding sites could be distinct receptors or a single receptor that changes affinity depending on the concentration of ligand present. The high-affinity binding sites for PGE2 on the sarcolemmal membrane have the same affinity as previously identified PGE2 receptors in other tissues. 8 -11 PGE2 has been demonstrated to have marked effects on heart function in a number of species, including rat, cat, dog, rabbit, sheep, and humans (for review, see Karmazyn and Dhalla 1 ). Our results suggest that these effects are mediated by the binding of PGE2 to specific receptors on the myocyte itself. Species differences in the response of the heart to PGE2 may be mediated by differences in receptor binding characteristics. It is interesting to note that the existence of two classes of PGE2 binding sites appears to be conserved not only between species, but also between tissues. In recent studies, we demonstrated that PGEz binds to bovine uterine smooth muscle with two classes of binding sites (R. Lerner, G.D. Lopaschuk, and P.M. Olley, unpublished observations). Two classes of PGEj binding sites have also been identified in other tissue such as human platelets, hen oviduct, canine medullary membranes, and rabbit cortical collecting tubule. 8 -11 -31 Binding of PGE2 to the high-affinity sites on the sarcolemmal membrane results in an inhibition of adenylate cyclase. PGE2 probably exerts its effects on myocardial contractility and heart rate through receptors coupled to adenylate cyclase. Inhibition of adenylate cyclase by PGE2 has also been demonstrated in other tissues. 10 32 reported that PGE2 also inhibits hormoneinduced cAMP accumulation in hepatocytes. The actual mechanism by which prostaglandins mediate cAMP levels, however, has not been measured directly. One reason for this is the difficulty in simultaneously accessing the prostaglandin receptor on one side of the membrane and the catalytic subunit of adenylate cyclase on the other side. In this report, we demonstrate that alamethicinpermeabilized cardiac sarcolemmal vesicles are a useful tool for studying prostaglandin receptorresponse coupling. In initial studies with this preparation, the effect of PGE2 on adenylate cyclase activity varied. In a number of preparations, we found that PGE2 inhibited adenylate cyclase at low concentrations, whereas in other preparations, no effect of PGEj was seen. The reason for this variability may involve uncoupling of the PGE receptor from the GTP binding protein(s) during isolation of the sarcolemmal vesicles. Recently, Negishi et al 26 demonstrated that occupancy of the PGE2 receptor on adrenal medullar membranes by PGE2 promotes the interaction of the receptor with the GTP binding protein(s). In our studies, initial preparation of cardiac sarcolemmal vesicles in the presence of PGE2 appears to maintain the coupling between the PGEz-inhibited adenylate cyclase at concentrations that occupy the high-affinity receptor.
The suggestion that the PGE2 receptor is coupled to adenylate cyclase activity via G proteins in cardiac sarcolemmal membranes is supported by studies in other tissues. In cultured hepatocytes, the inhibitory effect of PGE2 on cAMP accumulation is abolished by pertussis toxin, which suggests the involvement of a G s protein. 32 In renal medulla, Watanabe et al 31 demonstrated that the PGE2 receptor is coupled to pertussis toxin-sensitive G regulatory protein. GTP analogues added to a digitoninsolubilized microsomal preparation altered PGE2 binding kinetics, an effect that was reversed by pertussis toxin. Adenylate cyclase was not measured in this experimental system. In adrenal medulla, Negishi et al 26 found that the PGE2 receptor can be covalently cross-linked to a GTP-binding protein, and that it is a pertussis toxin-insensitive G protein that is not coupled to adenylate cyclase. They speculate that in adrenal medulla, the PGE receptor may initiate its response via phospholipase C stimulation. In the heart, our data suggest that PGE2 (and possibly PGEi) acts through a receptor coupled to Gj, which results in inhibition of adenylate cyclase. The possibility also exists that PGE? and PGE, interact with other hormones by acting on common catalytic subunits of adenylate cyclase via these G proteins. This possibility remains to be determined.
PGE2 attenuates the response of adipocytes, fibroblasts, and the renal medulla to /3-adrenergic agonists 33 -35 as well as renal tissue to vasopressin. 11 Strasser et al 36 demonstrate that in smooth muscle cells, PGE, promotes the translocation of a £-adrenergic receptor kinase from the cytosol to the plasma membrane. This translocation occurs concomitantly with homologous desensitization of the PGE, receptor. Whether PGE receptor desensitization occurs through phosphorylation has yet to be determined. The alamethicin-permeabilized cardiac sarcolemmal preparation used in this study should prove a useful tool in investigating this.
In summary, we demonstrate that high-affinity, stereospecific binding sites for PGE2 exist on the cardiac sarcolemmal membrane. Binding of PGE^ to its receptors is coupled to adenylate cyclase, possibly via guanine regulatory proteins. Use of isolated cardiac sarcolemmal vesicles should prove useful in further characterizing the direct actions of eicosanoids on the heart.
